Nasdaq · Healthcare
REGENXBIO Inc. (RGNX)
As-reported financials and recent SEC filings for REGENXBIO Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$170.4M
Net income
$-193.9M
Net margin
-113.8%
Diluted EPS
$-3.76
ROE
-188.7%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $170.4M | $83.3M | $90.2M | $112.7M | $470.3M |
| Gross profit | — | $49.8M | $53.0M | $58.2M | $418.5M |
| Operating income | $-161.2M | $-233.3M | $-268.1M | $-262.9M | $160.0M |
| Net income | $-193.9M | $-227.1M | $-263.5M | $-280.3M | $127.8M |
| Diluted EPS | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $2.91 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-06
View on EDGAR →42026-07-06
View on EDGAR →SC TO-I/A2026-07-06
View on EDGAR →1442026-07-01
View on EDGAR →42026-07-01
View on EDGAR →SC TO-I/A2026-07-01
View on EDGAR →8-K2026-06-29
View on EDGAR →SC TO-I2026-06-03
View on EDGAR →Largest Healthcare peers
Go deeper on RGNX
Search REGENXBIO Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.